(TheNewswire)
Calgary , Alberta – TheNewswire - November 9 , 2023 – nDatalyze Corp. (“NDAT” or the“Corporation”) (CSE:NDAT) (OTC:NDATF) announces that on November8, 2023, NDAT signed a Letter of Intent (“LOI”) with PersonalizedPrescribing (“PP”) which LOI contemplates the addition of a DNAadjunct to NDAT’s previously-announcedclinical study. The LOI anticipates a final agreement within 30 days,which agreement is to include PP’s provision of existing DNA datafor up to 200 Participants in the 18-29 year age group. It is expectedthat Participants will complete NDAT’s biometric questionnaire withthe answers combined with associated DNA data for submission to amachine-learning correlation process that is already planned formachine-learning aspect of the clinical study. Participants will becompensated by NDAT at a modest rate typical for this type ofnon-invasive survey.
James Durward, CEO/CTO states: “We’ve always hadDNA expressions in our database and we’ve always envisioned theaddition of raw DNA data that may be used as support correlation forour mental condition predictions. This relationship provides multipletangible and intangible benefits including access to an existing DNAdatabase where we can solicit questionnaire enrollment without havingto pay the costs of DNA tests. Furthermore, PP has deep knowledge ofDNA-related drug interactions and this may fit well with our goal ofnot only reducing misdiagnosis, but also reducing misprescriptionsthat often lead to poor outcomes and lower overall societal mentalhealth.”
AboutPersonalized Prescribing : Personalized Prescribing is committed todeveloping world-leading pharmacogenetic algorithms and technology toensure individuals receive the right drug, in the right dose, withoutsuffering through months and, often years, of drug failure andunnecessary side effects. Their motto is:“ Create anew standard of patient care in psychiatry that is based on objectivedata and clear science.” Personalized Prescribing’s genetic tests are covered by multiplehealth benefits providers. Their website is athttps://personalizedprescribing.com/
About YMI: YMIuses evidence-based, objective data from whole life experiences topredict individual mental states over time and applies this knowledgetowards a fuller understanding of how mental health develops and toimprove mental wellbeing. YMI combines machine-learning with aproprietary Reference Database that contains >1200 person’sgenetic expressions, childhood environment, habits, phobias, livedexperiences and lifestyle to generate a personalized graphic reportpredicting an individual’s predisposition toward a variety of commonmental conditions, both current and forward in time.
For Further Information, PleaseContact:
James Durward, CEO&CTO
Telephone: (403) 689-3901
Email: jimd@ndatalyze.com
nDatalyze Website: https://www.ndatalyze.com
YMI Website: https://ymihealth.ca
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in the policiesof the Canadian Securities Exchange) accepts responsibility for theadequacy or accuracy of this release. This news release does notconstitute an offer to sell or a solicitation of an offer to sell anyof the securities in the United States. The securities have not beenand will not be registered under the United States Securities Act of1933, as amended (the "U.S. Securities Act") or any statesecurities laws and may not be offered or sold within the UnitedStates or to U.S. Persons unless registered under the U.S. SecuritiesAct and applicable state securities laws or an exemption from suchregistration is available.
The information in this news release includes certaininformation and statements about management's view of future events,expectations, plans and prospects that constitute forward lookingstatements. These statements are based upon assumptions that aresubject to significant risks and uncertainties. Because of these risksand uncertainties and as a result of a variety of factors, the actualresults, expectations, achievements or performance may differmaterially from those anticipated and indicated by theseforward-looking statements. Any number of factors could cause actualresults to differ materially from these forward-looking statements aswell as future results. Although the Corporation believes that theexpectations reflected in forward looking statements are reasonable,it can give no assurances that the expectations of any forward-lookingstatements will prove to be correct. Except as required by law, theCorporation disclaims any intention and assumes no obligation toupdate or revise any forward-looking statements to reflect actualresults, whether as a result of new information, future events,changes in assumptions, changes in factors affecting suchforward-looking statements or otherwise.
Copyright (c) 2023 TheNewswire - All rights reserved.